See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Donald Trump
Baseball
Trade War
Stock Markets
Natural Disasters
Social Media
Golf
Trade
Artificial Intelligence
Wall Street
European Union
hcplive.com image

News from hcplive.com

Information about hcplive.com

Where is hcplive.com located?hcplive.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top hcplive.com News

IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
FDA · United States

IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval

58% Center coverage: 12 sources
(MedPage Today) -- The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday. The tablets are indicated...See the Story
Las Vegas colon cancer survivor credits early screening with saving life
Health

Las Vegas colon cancer survivor credits early screening with saving life

60% Center coverage: 5 sources
LAS VEGAS (KLAS) -- A Las Vegas colon cancer survivor credits early screening with saving her life. According to the American Cancer Society, colon cancer is now the leading cause of cancer-related deaths among men under 50 and the second among women under 50. “In the last 20 years, we have seen a significant increase of patients in their 20s, 30s, and 40s,” Dr. Ovunc Bardakcioglu, Professor and Colon and Rectal Surgery Chief for UNLV’s Departme…See the Story
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns - Aldeyra Therapeutics (NASDAQ:ALDX)
FDA · United States

FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns - Aldeyra Therapeutics (NASDAQ:ALDX)

67% Center coverage: 3 sources
The FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025.See the Story

Innovation

AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.See the Story

Micro-CT and Histological Assessment of Renal Arterial Embolization with Glubran®2 Cyanoacrylate: A Medium-Term Follow-Up Study in a Rabbit Model

Background Cyanoacrylate glues are widely used in interventional radiology as effective embolic agents due to their rapid polymerization and ability to achieve vessel occlusion. Nonetheless, concern remains regarding cast stability and potential recanalization over time. This study us...See the Story

Platelet-to-Neutrophil Ratio Associated with Predicting DME

Used as a biomarker across many specialties, the platelet-to-neutrophil ratio may soon enter ophthalmology for diabetic macular edema prediction.See the Story

Systematic Review Highlights Post-Pandemic Disparities in Pediatric Atopic Dermatitis

This review highlights disparities among patients of color in terms of atopic dermatitis prevalence, management, and outcomes in the post-COVID-19 world.See the Story

Multispecialty Perspectives on Shared Decision-Making in Atopic Dermatitis Care

Panelists discuss how shared decision-making in atopic dermatitis care involves collaboration between health care providers and patients, considering individual preferences, values, and treatment goals. This approach enhances treatment adherence and improves outcomes through personalized, informed choices.See the Story
United States · United States

Clinical Considerations for Choosing a Systemic Agent for Patients With Atopic Dermatitis

Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.See the Story

Overview of the Biologics Approved in Atopic Dermatitis

Panelists discuss how the current biologic landscape for atopic dermatitis includes 4 distinct agents with complementary mechanisms: dupilumab targeting IL-4 and IL-13 pathways to broadly inhibit type 2 inflammation, lebrikizumab and tralokinumab both selectively blocking IL-13 to potentially offer similar efficacy with refined targeting, and nemolizumab uniquely addressing the IL-31 “itch cytokine” pathway—each representing different strategic …See the Story

Rapamycin Improves PROMs in Patients With ME/CFS in Early Trial

Statistically significant improvements were seen in BAS, MFI, SF-36 subscores, SSS fatigue, disrupted sleep. PEM, and orthostatic intolerance.See the Story

Breaking News Topics Related to hcplive.com

Maryland

Maryland

Health

Health

United States

United States

Medical

Medical

FDA

FDA

Our use of cookies
Unlike other news sites, we do not share or sell your data to third-parties for targeted ads.
By continuing to use our application or website, you agree to our Terms of Service and Privacy Policy.
News
For You
SearchBlindspotLocal